Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013

Infection, Genetics and Evolution

Volumn 26, Issue , 2014, Pages 65-71

  Huhti, Leena ^a   Blazevic, Vesna ^a   Puustinen, Leena ^a   Hemming, Maria ^a   Salminen, Marjo ^a   Vesikari, Timo ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Acute gastroenteritis; Children; GII.4 genotype; Norovirus; Variants

Indexed keywords

ACUTE GASTROENTERITIS; ADOLESCENT; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; FINLAND; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MOLECULAR PHYLOGENY; NONHUMAN; NOROVIRUS; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS LIKE AGENT; VIRUS STRAIN; ANTIGENIC VARIATION; CALICIVIRIDAE INFECTIONS; CHILD; CLASSIFICATION; DNA SEQUENCE; EPIDEMIC; GASTROENTERITIS; GENETICS; HISTORY; IMMUNOLOGY; INFANT; NEWBORN; PHYLOGENY; PRESCHOOL CHILD; PREVALENCE; VIROLOGY; VIRUS GENE;

EPITOPE;

ADOLESCENT; ANTIGENIC VARIATION; CALICIVIRIDAE INFECTIONS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; EPITOPES; FINLAND; GASTROENTERITIS; GENES, VIRAL; GENETIC VARIATION; GENOTYPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; NOROVIRUS; PHYLOGENY; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 84901601567     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2014.05.003     Document Type: Article

References (56)

1. Allen D.J., Gray J.J., Gallimore C.I., Xerry J., Iturriza-Gomara M. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 2008, 3:e1485.
2. Ball J.M., Graham D.Y., Opekun A.R., Gilger M.A., Guerrero R.A., Estes M.K. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999, 117:40-48.
3. Blazevic V., Lappalainen S., Nurminen K., Huhti L., Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011, 29:8126-8133.
4. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 1990, 28:495-503.
5. Buesa J., Collado B., Lopez-Andujar P., Abu-Mallouh R., Rodriguez Diaz J., Garcia Diaz A., Prat J., Guix S., Llovet T., Prats G., Bosch A. Molecular epidemiology of caliciviruses causing outbreaks and sporadic cases of acute gastroenteritis in Spain. J. Clin. Microbiol. 2002, 40:2854-2859.
6. Cao S., Lou Z., Tan M., Chen Y., Liu Y., Zhang Z., Zhang X.C., Jiang X., Li X., Rao Z. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 2007, 81:5949-5957.
7. Debbink K., Donaldson E.F., Lindesmith L.C., Baric R.S. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 2012, 86:1214-1226.
8. Debbink K., Lindesmith L.C., Donaldson E.F., Costantini V., Beltramello M., Corti D., Swanstrom J., Lanzavecchia A., Vinje J., Baric R.S. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 2013, 208:1877-1887.
9. Farkas T., Zhong W.M., Jing Y., Huang P.W., Espinosa S.M., Martinez N., Morrow A.L., Ruiz-Palacios G.M., Pickering L.K., Jiang X. Genetic diversity among sapoviruses. Arch. Virol. 2004, 149:1309-1323.
10. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. N. Engl. J. Med. 2009, 361:1776-1785.
11. Green K.Y. Caliciviridae: the noroviruses. Fields Virology 2013, Lippincott William & Wilkins (LWW), (Section 20). 6th ed. D.M. Knipe, P. Howley (Eds.).
12. Harrington P.R., Lindesmith L., Yount B., Moe C.L., Baric R.S. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 2002, 76:12335-12343.
13. Hemming M., Rasanen S., Huhti L., Paloniemi M., Salminen M., Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur. J. Pediatr. 2013, 172:739-746.
14. Huhti L., Blazevic V., Nurminen K., Koho T., Hytonen V.P., Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch. Virol. 2010, 155:1855-1858.
15. Jiang X., Huang P.W., Zhong W.M., Farkas T., Cubitt D.W., Matson D.O. Design and evaluation of a primer pair that detects both Norwalk- and Sapporo-like caliciviruses by RT-PCR. J. Virol. Methods 1999, 83:145-154.
16. Jiang X., Wang M., Graham D.Y., Estes M.K. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 1992, 66:6527-6532.
17. Koho T., Huhti L., Blazevic V., Nurminen K., Butcher S.J., Laurinmaki P., Kalkkinen N., Ronnholm G., Vesikari T., Hytonen V.P., Kulomaa M.S. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J. Virol. Methods 2012, 179:1-7.
18. Kroneman A., Vega E., Vennema H., Vinje J., White P.A., Hansman G., Green K., Martella V., Katayama K., Koopmans M. Proposal for a unified norovirus nomenclature and genotyping. Arch. Virol. 2013, 158:2059-2068.
19. Kroneman A., Vennema H., Harris J., Reuter G., von Bonsdorff C.H., Hedlund K.O., Vainio K., Jackson V., Pothier P., Koch J., Schreier E., Bottiger B.E., Koopmans M., Food-borne viruses in Europe network Increase in norovirus activity reported in Europe. Euro Surveill. 2006, 11:E061214.1.
20. Kumar S., Tamura K., Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 2004, 5:150-163.
21. Lindesmith L.C., Beltramello M., Donaldson E.F., Corti D., Swanstrom J., Debbink K., Lanzavecchia A., Baric R.S. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 2012, 8:e1002705.
22. Lindesmith L.C., Costantini V., Swanstrom J., Debbink K., Donaldson E.F., Vinje J., Baric R.S. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J. Virol. 2013, 87:2803-2813.
23. Lindesmith L.C., Debbink K., Swanstrom J., Vinje J., Costantini V., Baric R.S., Donaldson E.F. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J. Virol. 2012, 86:873-883.
24. Lindesmith L.C., Donaldson E.F., Baric R.S. Norovirus GII.4 strain antigenic variation. J. Virol. 2011, 85:231-242.
25. Lindesmith L.C., Donaldson E.F., Lobue A.D., Cannon J.L., Zheng D.P., Vinje J., Baric R.S. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 2008, 5:e31.
26. Lopman B., Vennema H., Kohli E., Pothier P., Sanchez A., Negredo A., Buesa J., Schreier E., Reacher M., Brown D., Gray J., Iturriza M., Gallimore C., Bottiger B., Hedlund K.O., Torven M., von Bonsdorff C.H., Maunula L., Poljsak-Prijatelj M., Zimsek J., Reuter G., Szucs G., Melegh B., Svennson L., van Duijnhoven Y., Koopmans M. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 2004, 363:682-688.
27. Lopman B.A., Brown D.W., Koopmans M. Human caliciviruses in Europe. J. Clin. Virol. 2002, 24:137-160.
28. Noel J.S., Fankhauser R.L., Ando T., Monroe S.S., Glass R.I. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J. Infect. Dis. 1999, 179:1334-1344.
29. Nurminen K., Blazevic V., Huhti L., Rasanen S., Koho T., Hytonen V.P., Vesikari T. Prevalence of norovirus GII-4 antibodies in Finnish children. J. Med. Virol. 2011, 83:525-531.
30. Pang X.L., Honma S., Nakata S., Vesikari T. Human caliciviruses in acute gastroenteritis of young children in the community. J. Infect. Dis. 2000, 181(Suppl. 2):S288-S294.
31. Pang X.L., Joensuu J., Vesikari T. Human calicivirus-associated sporadic gastroenteritis in Finnish children less than two years of age followed prospectively during a rotavirus vaccine trial. Pediatr. Infect. Dis. J. 1999, 18:420-426.
32. Pang X.L., Preiksaitis J.K., Lee B. Multiplex real time RT-PCR for the detection and quantitation of norovirus genogroups I and II in patients with acute gastroenteritis. J. Clin. Virol. 2005, 33:168-171.
33. Pang X.L., Preiksaitis J.K., Wong S., Li V., Lee B.E. Influence of novel norovirus GII.4 variants on gastroenteritis outbreak dynamics in Alberta and the Northern Territories, Canada between 2000 and 2008. PLoS One 2010, 5:e11599.
34. Parra G.I., Bok K., Taylor R., Haynes J.R., Sosnovtsev S.V., Richardson C., Green K.Y. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012, 30:3580-3586.
35. Patel M.M., Widdowson M.A., Glass R.I., Akazawa K., Vinje J., Parashar U.D. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 2008, 14:1224-1231.
36. Payne D.C., Vinje J., Szilagyi P.G., Edwards K.M., Staat M.A., Weinberg G.A., Hall C.B., Chappell J., Bernstein D.I., Curns A.T., Wikswo M., Shirley S.H., Hall A.J., Lopman B., Parashar U.D. Norovirus and medically attended gastroenteritis in U.S. children. N. Engl. J. Med. 2013, 368:1121-1130.
37. Prasad B.V., Hardy M.E., Dokland T., Bella J., Rossmann M.G., Estes M.K. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999, 286:287-290.
38. Puustinen L., Blazevic V., Huhti L., Szakal E.D., Halkosalo A., Salminen M., Vesikari T. Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007. Epidemiol. Infect. 2012, 140:268-275.
39. Puustinen L., Blazevic V., Salminen M., Hamalainen M., Rasanen S., Vesikari T. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand. J. Infect. Dis. 2011, 43:804-808.
40. Rasanen S., Lappalainen S., Salminen M., Huhti L., Vesikari T. Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. Eur. J. Pediatr. 2011, 170:1413-1418.
41. Reeck A., Kavanagh O., Estes M.K., Opekun A.R., Gilger M.A., Graham D.Y., Atmar R.L. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 2010, 202:1212-1218.
42. Rockx B., Baric R.S., de Grijs I., Duizer E., Koopmans M.P. Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J. Med. Virol. 2005, 77:439-446.
43. Siebenga J.J., Lemey P., Kosakovsky Pond S.L., Rambaut A., Vennema H., Koopmans M. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog. 2010, 6:e1000884.
44. Siebenga J.J., Vennema H., Renckens B., de Bruin E., van der Veer B., Siezen R.J., Koopmans M. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 2007, 81:9932-9941.
45. Siebenga J.J., Vennema H., Zheng D.P., Vinje J., Lee B.E., Pang X.L., Ho E.C., Lim W., Choudekar A., Broor S., Halperin T., Rasool N.B., Hewitt J., Greening G.E., Jin M., Duan Z.J., Lucero Y., O'Ryan M., Hoehne M., Schreier E., Ratcliff R.M., White P.A., Iritani N., Reuter G., Koopmans M. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 2009, 200:802-812.
46. Tamminen K., Huhti L., Koho T., Lappalainen S., Hytonen V.P., Vesikari T., Blazevic V. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2012, 135:89-99.
47. Tamminen K., Lappalainen S., Huhti L., Vesikari T., Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013, 8:e70409.
48. Tan M., Huang P., Meller J., Zhong W., Farkas T., Jiang X. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J. Virol. 2003, 77:12562-12571.
49. Tu E.T., Bull R.A., Greening G.E., Hewitt J., Lyon M.J., Marshall J.A., McIver C.J., Rawlinson W.D., White P.A. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clin. Infect. Dis. 2008, 46:413-420.
50. van Beek J., Ambert-Balay K., Botteldoorn N., Eden J.S., Fonager J., Hewitt J., Iritani N., Kroneman A., Vennema H., Vinje J., White P.A., Koopmans M., NoroNet Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. Euro Surveill. 2013, 18:8-9.
51. Vega E., Barclay L., Gregoricus N., Williams K., Lee D., Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg. Infect. Dis. 2011, 17:1389-1395.
52. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., Ward R.L., Schodel F., Karvonen A., Drummond J.E., DiNubile M.J., Heaton P.M. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829.
53. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur. J. Pediatr. 2010, 169:1379-1386.
54. Vesikari T., Karvonen A., Puustinen L., Zeng S.Q., Szakal E.D., Delem A., De Vos B. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J. 2004, 23:937-943.
55. Vesikari T., Karvonen A.V., Majuri J., Zeng S.Q., Pang X.L., Kohberger R., Forrest B.D., Hoshino Y., Chanock R.M., Kapikian A.Z. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis. 2006, 194:370-376.
56. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., Dallas M.J., Heyse J.F., Goveia M.G., Black S.B., Shinefield H.R., Christie C.D., Ylitalo S., Itzler R.F., Coia M.L., Onorato M.T., Adeyi B.A., Marshall G.S., Gothefors L., Campens D., Karvonen A., Watt J.P., O'Brien K.L., Dinubile M.J., Clark H.F., Boslego J.W., Offit P.A., Heaton P.M., Rotavirus Efficacy and Safety Trial (REST) Study Team Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 2006, 354:23-33.